Tesla Recalls Model...
Health Care: Drugs
AEterna Zentaris Inc. (AEZS: NASDAQ)
$1.88 -0.02 | -1.28%
06/19/13 - 01:48 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.90 |
| 52 Week High | 5.63 |
| 52 Week Low | 1.70 |
| Avg. Daily Vol. (Mil) | 0.24 |
| Beta (3 year) | 2.86 |
| Share Related Items | |
| Mkt Cap (Mil) | 48.37 |
| Shares Out (Mil) | 25.46 |
| Float (Mil) | 25.25 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.90 |
| Current Ratio | 3.30 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 1.19 |
| Price/Book | 0.00 |
| Price/Cash Flow | -2.10 |
| Per Share Data | |
| Earnings | -0.33 |
| Sales | 1.60 |
| Book Value | 0.00 |
| Cash Flow | -0.92 |
| Business Summary | |
|---|---|
| AEterna Zentaris, Inc., is an oncology and endocrinology drug development company investigating treatments for various unmet medical needs. | |
| General Information | |
| 1405 du Parc-Technologique B
Quebec City, QC G1P 4P5 |
|
| www.aezsinc.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 81 | |
| CEO: Jurgen Engel | |
| Short Interest | |
| Current Month (Mil) | 1.24 |
| Previous Month (Mil) | 1.17 |
| Short Interest Ratio (Days) | 5.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -31.20 |
| Return on Investments | 467.00 |
| Profitability | |
| Gross Margin | 16.20 |
| EBIT Margin | -16.40 |
| Profit Margin | -45.50 |
Portfolios with AEZS
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- UserMillion Dollar Portfolio
- Userwright stocks
- UserSMITTY
- UserFiuza 1
- Userherb's portfolio
- Contributor10 Pharma Stocks Under $3
Latest AEZS Headlines from TheStreet
- 5 Stocks Under $10 Ready to Soar Higher 02.07.13 | 01:02 pm
- Biotech Stock Mailbag: Keryx, Sangamo, Threshold and Amarin 01.25.13 | 07:01 am
- 5 Biotech Stocks Rising on Unusual Volume 11.20.12 | 02:11 pm
- 5 Stocks Under $10 Set to Soar 09.20.12 | 01:09 pm
- Biotech Stock Mailbag: Navidea, Celsion, Raptor and Threshold 09.14.12 | 06:09 am
- 2012 Biotech Stock Predictions: An Interim Report Card 08.28.12 | 07:08 am
- ASCO '12 Stocks: Winners and Losers 06.04.12 | 06:06 am
- ASCO '12: Colon Cancer Drugs Good (Roche) and Very Bad (Keryx Pharma) 06.03.12 | 06:06 am
- Keryx: Lessons From a Drug Failure 04.02.12 | 12:04 pm
- AEterna Zentaris Stock Gaps Down On Today's Open (AEZS) 04.02.12 | 09:04 am
Press Releases for AEZS
- Aeterna Zentaris Announces Dismissal Of Class Action Lawsuit - PR Newswire 06.06.13 | 04:06 pm
- Aeterna Zentaris: Encouraging Final Data For Phase 1 Portion Of Ongoing Phase 1/2 Trial With Zoptarelin Doxorubicin (AEZS-108) In Prostate Cancer Reported At ASCO - PR Newswire 06.03.13 | 09:06 am
- Aeterna Zentaris Announces "At-the-Market" Issuance Program - PR Newswire 05.21.13 | 04:05 pm
- Aeterna Zentaris To Present At Upcoming Bloom Burton & Co. Healthcare Investor Conference In Toronto - PR Newswire 05.15.13 | 07:05 am
- Aeterna Zentaris To Announce First Quarter 2013 Financial And Operating Results On May 7, 2013 And Hold Annual Shareholders Meeting On May 8, 2013 - PR Newswire 05.01.13 | 07:05 am
- Aeterna Zentaris Newly Appointed CEO, David A. Dodd, To Host Introductory Analyst And Investor Conference Call On Thursday, April 25, 2013 - PR Newswire 04.23.13 | 04:04 pm
- Aeterna Zentaris Announces Transfer Of Manufacturing Rights Related To Cetrotide® To Merck KGaA - PR Newswire 04.17.13 | 07:04 am
- David A. Dodd Appointed President & Chief Executive Officer Of Aeterna Zentaris Inc. - PR Newswire 04.15.13 | 08:04 am
- Aeterna Zentaris Presents Encouraging Updated Data On Its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates At AACR Meeting - PR Newswire 04.10.13 | 04:04 pm
- Aeterna Zentaris And Ergomed Sign Co-Development And Profit Sharing Agreement For AEZS-108 In Endometrial Cancer - PR Newswire 04.10.13 | 07:04 am
Partner Headlines for AEZS
- 4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce - Seeking Alpha 11.20.12 | 09:11 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 11.05.12 | 09:11 am
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 11.01.12 | 09:11 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 10.19.12 | 09:10 am
- Aeterna Zentaris Announces Closing of $16.5 Million Public Offering of Common Shares and Warrants - Benzinga 10.17.12 | 09:10 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.16.12 | 09:10 am
- Pre-Market Most Active for Oct 12, 2012 : BAC, AMD, S, JPM, WFC, BCS, CLWR, ASML, NPSP, QQQ, SIRI, AEZS - NASDAQ 10.12.12 | 12:10 pm
- Under Construction Rehash: Buy Acadia And Astex - Seeking Alpha 09.20.12 | 09:09 am
- Healthcare Biz Recap: Aeterna Zentaris Shares Surge, J&J Files with FDA - Wall St. Cheat Sheet 05.31.12 | 10:05 am
- Stocks To Watch: Week Of March 19-23 - Seeking Alpha 03.21.12 | 08:03 am
